Shuffler News
  • Home
  • Shuffles Music
  • Site Owners Choice
  • Parkinsons
    • Parkinsons News
    • Homeless
  • Domapine Agonists
    • Add your Agonist Story
    • Show Agonist Stories
  • Login and Register
Select Page
Dosing begins in phase 1 safety study of new LRRK2 inhibitor

Dosing begins in phase 1 safety study of new LRRK2 inhibitor

by Steve Bryson PhD | Feb 9, 2023 | Parkinsons

Dosing has begun in a Phase 1 clinical trial of healthy volunteers to evaluate the safety and pharmacological properties of NEU-723, Neuron23’s oral investigational treatment for Parkinson’s disease. The small molecule candidate therapy is designed to

Variability in platelet size may be biomarker for Parkinson’s: Study

Variability in platelet size may be biomarker for Parkinson’s: Study

by Steve Bryson PhD | Feb 7, 2023 | Parkinsons

Researchers have discovered a new genetic link between platelets in the bloodstream and Parkinson’s disease, according to a large-scale genetic study that investigated associations between blood measures and neurological and psychiatric diseases. Variation in platelet

Nerve Cell Pentraxin Proteins May Be New Biomarkers in Parkinson’s

by Steve Bryson PhD | Jan 17, 2023 | Parkinsons

Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated with motor and cognitive decline in people with Parkinson’s disease and related conditions, a study

Trial Testing Cough Medicine Ambroxol Starting Soon

Trial Testing Cough Medicine Ambroxol Starting Soon

by Steve Bryson PhD | Jan 14, 2023 | Parkinsons

The world-first Phase 3 clinical trial testing the ability of ambroxol, a medicine used for decades to treat lung conditions, to slow Parkinson’s disease progression is expected to start in the next few months. Called

Trial Testing Psilocybin in Parkinson’s Nears End

by Steve Bryson PhD | Jan 13, 2023 | Parkinsons

A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored

Categories

  • Yelp
  • Facebook
  • Twitter
  • Instagram
  • Email
  • Privacy Policy
  • Facebook
  • Twitter
  • Instagram
  • RSS

Designed by Elegant Themes | Powered by WordPress